ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

ImmunityBio and Bayer side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

ImmunityBioBayer
studies on the registry1151,694
open to participants now1260
phase 3 studies under way211
reach primary completion within a year635
programswith a study of their own in two years1021

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseImmunityBioBayer
Phase 1

ImmunityBio: 3 of its 10 programs at phase 1

  1. CD19 t-haNKphase 1
  2. sotevtamabphase 1
  3. zabadinostatphase 1
30%
19%
Phase 250%

Bayer: 8 of its 21 programs at phase 2

  1. AB-1005phase 2
  2. WRN Inhibitor RO7589831phase 2
  3. nurandociguatphase 2
  4. BAY 3401016phase 2
  5. BAY 3670549phase 2

and 3 more — sign in to see them all

38%
Phase 3

ImmunityBio: 2 of its 10 programs at phase 3

  1. nogapendekin alfa inbakiceptphase 3
  2. BCG Vaccinephase 3
20%

Bayer: 4 of its 21 programs at phase 3

  1. elinzanetantphase 3
  2. sevabertinibphase 3
  3. bemdaneprocelphase 3
  4. aficamtenphase 3
19%
Approved, new studies00%

Bayer: 5 of its 21 programs at approved, new studies

  1. finerenoneapproved, new study
  2. darolutamideapproved, new study
  3. Aspirinapproved, new study
  4. acoramidisapproved, new study
  5. Levonorgestrelapproved, new study
24%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
ImmunityBio3 readouts · 0 phase 3

ImmunityBio, Nov ’26: 2 programs whose next study reaches primary completion

  1. BCG Vaccinephase 3 · Nov 0 · NCT06829823
  2. nogapendekin alfa inbakiceptphase 3 · Nov 0 · NCT06829823
·····

ImmunityBio, May ’27: 1 program whose next study reaches primary completion

  1. CD19 t-haNK- IV Administrationphase 2 · May 25 · NCT07125872
·····
Bayer10 readouts · 4 phase 3·

Bayer, Dec ’26: 1 program whose next study reaches primary completion

  1. BAY 3389934phase 1 · Dec 25 · NCT06854640

Bayer, Jan ’27: 1 program whose next study reaches primary completion

  1. elinzanetantphase 3 · Jan 22 · NCT07762287
·

Bayer, Mar ’27: 1 program whose next study reaches primary completion

  1. Aspirinapproved, new study · Mar 10 · NCT07652723

Bayer, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. finerenoneapproved, new study · Apr 10 · NCT05196035

Bayer, May ’27: 2 programs whose next study reaches primary completion

  1. nurandociguatphase 2 · May 7 · NCT07431294
  2. WRN Inhibitor RO7589831phase 2 · May 31 · NCT06004245
·

Bayer, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. darolutamideapproved, new study · Jul 30 · NCT05794906

Bayer, Aug ’27: 1 program whose next study reaches primary completion

  1. RAS/PI3K-alpha Inhibitor VVD-159642phase 1 · Aug 1 · NCT06804824

Bayer, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. acoramidisapproved, new study · Sep 17 · NCT07298044

Bayer, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. sevabertinibphase 3 · Oct 28 · NCT06452277
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

ImmunityBio

New programs 0

None

Reached a new phase 0

None

Study stopped 1

Primary completion later 1

Bayer

New programs 0

None

Reached a new phase 1

Study stopped 0

None

Primary completion later 2

Where they overlap

Conditions where at least two of them have programs: 5 in all. A program counts in each condition its studies name most.

ConditionImmunityBioBayer
Carcinoma, Non-Small-Cell Lungboth · compare here

ImmunityBio in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. nogapendekin alfa inbakiceptphase 3
  2. sotevtamabphase 1

Their studies: ImmunityBio’s studies of Carcinoma, Non-Small-Cell Lung in search

Bayer in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. sevabertinibphase 3
  2. PRMT5 Inhibitor BAY 3713372phase 2

Their studies: Bayer’s studies of Carcinoma, Non-Small-Cell Lung in search

Neoplasm Metastasisboth · compare here

ImmunityBio in Neoplasm Metastasis: 2 programs

  1. memory cytokine-enhanced NK cellsphase 2
  2. sotevtamabphase 1

Their studies: ImmunityBio’s studies of Neoplasm Metastasis in search

Bayer in Neoplasm Metastasis: 1 program

  1. darolutamideapproved, new study

Their studies: Bayer’s studies of Neoplasm Metastasis in search

Prostatic Neoplasmsboth · compare here

ImmunityBio in Prostatic Neoplasms: 2 programs

  1. memory cytokine-enhanced NK cellsphase 2
  2. ETBX-071phase 2

Their studies: ImmunityBio’s studies of Prostatic Neoplasms in search

Bayer in Prostatic Neoplasms: 1 program

  1. darolutamideapproved, new study

Their studies: Bayer’s studies of Prostatic Neoplasms in search

Colorectal Neoplasmsboth · compare here

ImmunityBio in Colorectal Neoplasms: 1 program

  1. sotevtamabphase 1

Their studies: ImmunityBio’s studies of Colorectal Neoplasms in search

Bayer in Colorectal Neoplasms: 1 program

  1. WRN Inhibitor RO7589831phase 2

Their studies: Bayer’s studies of Colorectal Neoplasms in search

Neoplasmsboth · compare here

Bayer in Neoplasms: 1 program

  1. darolutamideapproved, new study

Their studies: Bayer’s studies of Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: ImmunityBio 2 of 10 · Bayer 13 of 21 programs (14 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.